Want to see SION full AI Analyst Report?
SION Stock Chart & Stats
$6.17
$1.64(3.72%)
At close: 4:00 PM EDT
$6.17
$1.64(3.72%)
Day’s Range― - ―
52-Week Range$4.01 - $54.97
Previous CloseN/A
Volume654.94K
Average Volume (3M)1.32M
Market Cap
$212.05M
Enterprise Value$1.78B
Total Cash (Recent Filing)$211.03M
Total Debt (Recent Filing)$8.07M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 11, 2026EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding45,212,400
10 Day Avg. Volume973,414
30 Day Avg. Volume1,324,650
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.36
Price to Sales (P/S)0.00
P/FCF Ratio-24.66
Enterprise Value/Market Cap8.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.83K
Enterprise Value/Ebitda-19.11
Forecast
1Y Price Target
$15.33Price Target Upside148.51% Upside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)-2.53
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage relative to equity gives Sionna financial flexibility while it funds clinical development. The modest debt burden should reduce refinancing and interest pressure, allowing more of its available capital to support research and clinical priorities.
Extended Cash RunwayA projected cash runway into the second half of 2029 provides time to generate clinical data without immediate financing pressure. This supports disciplined pipeline prioritization and gives management greater flexibility to advance or partner programs.
Lead Dual Combination AdvancementThe preferred SION-451/SION-2222 combination has cleared initial safety, tolerability, and pharmacokinetic objectives, supporting continued development. Its planned Phase 2a study creates a defined catalyst for testing clinical activity in cystic fibrosis patients.
Bears Say
Pre-Revenue And Widening LossesSionna has no reported revenue and remains structurally loss-making, with losses widening as development spending continues. Without an approved product or recurring commercial sales, the company has limited internal earnings capacity to fund its pipeline.
Persistent Cash BurnThe large and worsening cash outflow means Sionna consumes capital rather than generating funds from operations. Continued clinical development therefore depends on existing reserves and potentially future financing or partnering proceeds, limiting long-term financial self-sufficiency.
Clinical Setback And Pipeline CutbackThe Phase 2a failure of SION-719 as an add-on removes one development path and reduces pipeline breadth. The associated program wind-down and restructuring concentrate resources on fewer assets, increasing dependence on the dual-combination strategy.
Sionna Therapeutics, Inc. News
SION FAQ
What was Sionna Therapeutics, Inc.’s price range in the past 12 months?
Sionna Therapeutics, Inc. lowest stock price was $4.01 and its highest was $54.97 in the past 12 months.
What is Sionna Therapeutics, Inc.’s market cap?
Sionna Therapeutics, Inc.’s market cap is $212.05M.
When is Sionna Therapeutics, Inc.’s upcoming earnings report date?
Sionna Therapeutics, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 29 days.
How were Sionna Therapeutics, Inc.’s earnings last quarter?
Sionna Therapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.66 earnings per share for the quarter, missing the consensus estimate of -$0.65 by -$0.01.
Is Sionna Therapeutics, Inc. overvalued?
According to Wall Street analysts Sionna Therapeutics, Inc.’s price is currently Undervalued.
Does Sionna Therapeutics, Inc. pay dividends?
Sionna Therapeutics, Inc. does not currently pay dividends.
What is Sionna Therapeutics, Inc.’s EPS estimate?
Sionna Therapeutics, Inc.’s EPS estimate is -0.64.
How many shares outstanding does Sionna Therapeutics, Inc. have?
Sionna Therapeutics, Inc. has 45,212,400 shares outstanding.
What happened to Sionna Therapeutics, Inc.’s price movement after its last earnings report?
Sionna Therapeutics, Inc. reported an EPS of -$0.66 in its last earnings report, missing expectations of -$0.65. Following the earnings report the stock price went up 4.795%.
Which hedge fund is a major shareholder of Sionna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in SION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sionna Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$15.33 (148.51% Upside)
$15.33 (148.51% Upside)
Blogger Sentiment
Neutral
SION Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 265.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $21.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 11.3%
Last 30 Days ▼ 11.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.05%
12-Months-Change
Fundamentals
Return on Equity
-32.94%
Trailing 12-Months
Asset Growth
-19.54%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
SION Stock 12 Month Forecast
Average Price Target
$15.33
▲(148.51% Upside)
Technical Analysis
Sarepta Therapeutics
―
Intellia Therapeutics
―
Stoke Therapeutics
―
Beam Therapeutics
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
33.56% Insiders
9.59% Mutual Funds
12.57% Other Institutional Investors
37.16% Public Companies and
Individual Investors